BAUSCH + LOMB CORP

NYSE: BLCO (Bausch + Lomb Corporation)

Kemas kini terakhir: 12 Jan, 10:10PM

17.50

0.29 (1.69%)

Penutupan Terdahulu 17.21
Buka 17.16
Jumlah Dagangan 425,628
Purata Dagangan (3B) 420,391
Modal Pasaran 6,198,321,152
Harga / Pendapatan (P/E Ke hadapan) 17.15
Harga / Jualan (P/S) 1.21
Harga / Buku (P/B) 0.940
Julat 52 Minggu
10.45 (-40%) — 18.14 (3%)
Tarikh Pendapatan 29 Oct 2025
Margin Keuntungan -7.50%
Margin Operasi (TTM) -5.36%
EPS Cair (TTM) -1.02
Pertumbuhan Hasil Suku Tahunan (YOY) 3.50%
Jumlah Hutang/Ekuiti (D/E MRQ) 75.07%
Nisbah Semasa (MRQ) 1.56
Aliran Tunai Operasi (OCF TTM) 166.00 M
Aliran Tunai Bebas Leveraj (LFCF TTM) 69.00 M
Pulangan Atas Aset (ROA TTM) 0.61%
Pulangan Atas Ekuiti (ROE TTM) -5.36%

Arah Aliran Pasaran

Jangka Pendek Jangka Sederhana
Industri Medical Instruments & Supplies (US) Menaik Bercampur
Medical Instruments & Supplies (Global) Menaik Menurun
Stok Bausch + Lomb Corporation Menaik Bercampur

AISkor Stockmoo

-0.8
Konsensus Penganalisis 0.0
Aktiviti Orang Dalam NA
Volatiliti Harga -3.5
Purata Bergerak Teknikal 0.0
Osilator Teknikal 0.5
Purata -0.75

Saham Serupa

Stok Modal Pasaran DY P/E (TTM) P/B
BLCO 6 B - - 0.940
BDX 59 B 0.50% 35.43 2.32
WST 20 B 0.15% 41.01 5.58
ALC 38 B 0.35% 37.67 1.68
RMD 37 B 0.21% 25.71 6.02
STVN 5 B 0.21% 32.37 2.79

Bausch & Lomb is one of the largest vision care companies in the US. The firm was previously a subsidiary under parent company Bausch Health and it was spun off to become a public company in 2022. It operates in three segments: vision care, surgical, and ophthalmic pharmaceuticals. Vision care is composed of contact lenses, a market that B&L controls 10%, and ocular health products, which includes Biotrue and Lumify. Surgical includes a suite of intraocular lenses, equipment for cataract and vitreoretinal surgeries, as well as surgical instruments. Ophthalmic pharmaceuticals has a diverse lineup of products, including Xipere, Vyzulta, and Lotemax that treat different complications. With over 100 products, B&L has the largest portfolio of eye care prescriptions in the space.

Sektor Healthcare
Industri Medical Instruments & Supplies
Gaya Pelaburan Mid Core
% Dimiliki oleh Orang Dalam 88.13%
% Dimiliki oleh Institusi 10.97%

Pemilikan

Nama Tarikh Syer Dipegang
Icahn Carl C 30 Sep 2025 3,500,000
Goldentree Asset Management Lp 30 Sep 2025 2,660,508
Silver Point Capital L.P. 30 Sep 2025 2,565,000
Diameter Capital Partners Lp 30 Sep 2025 1,215,893
Compass Rose Asset Management, Lp 30 Sep 2025 1,000,000
Davidson Kempner Capital Management Lp 30 Sep 2025 980,474
Julat 52 Minggu
10.45 (-40%) — 18.14 (3%)
Julat Harga Sasaran
16.00 (-8%) — 21.00 (20%)
Tinggi 21.00 (Morgan Stanley, 20.00%) Beli
Median 17.50 (0.00%)
Rendah 16.00 (JP Morgan, -8.57%) Pegang
Purata 18.00 (2.86%)
Jumlah 4 Beli, 4 Pegang
Harga Purata @ Panggilan 15.65
Syarikat Tarikh Harga Sasaran Panggilan Harga @ Panggilan
Evercore ISI Group 05 Jan 2026 18.00 (2.86%) Pegang 16.80
30 Oct 2025 18.00 (2.86%) Beli 15.14
Morgan Stanley 02 Dec 2025 21.00 (20.00%) Beli 17.05
RBC Capital 14 Nov 2025 19.00 (8.57%) Beli 15.60
Wells Fargo 14 Nov 2025 17.00 (-2.86%) Pegang 15.60
30 Oct 2025 16.00 (-8.57%) Pegang 15.14
Barclays 31 Oct 2025 17.00 (-2.86%) Pegang 14.94
HC Wainwright & Co. 31 Oct 2025 17.00 (-2.86%) Beli 14.94
JP Morgan 30 Oct 2025 16.00 (-8.57%) Pegang 15.14
Raymond James 30 Oct 2025 19.00 (8.57%) Beli 15.14

Tiada data dalam julat masa ini.

Tarikh Jenis Butiran
23 Jan 2026 Pengumuman Bausch Health Provides Update on RED-C Phase 3 Clinical Trials
21 Jan 2026 Pengumuman Bausch Health to Announce Fourth Quarter and Full Year 2025 Results on February 18, 2026
20 Jan 2026 Pengumuman Bausch + Lomb Will Release Fourth-Quarter and Full-Year 2025 Financial Results on Feb. 18
05 Jan 2026 Pengumuman Bausch Health to Participate in the 44th Annual J.P. Morgan Healthcare Conference
05 Jan 2026 Pengumuman Bausch + Lomb Partners with Glaucoma Research Foundation and The Glaucoma Foundation to Address a Leading Cause of Irreversible Blindness in the U.S.
02 Jan 2026 Pengumuman Bausch + Lomb Completes Refinancing of Outstanding Term B Loans
23 Dec 2025 Pengumuman Bausch Health Announces Final Results and Expiration of Exchange Offers
23 Dec 2025 Pengumuman Bausch + Lomb to Participate in the 44th Annual J.P. Morgan Healthcare Conference
17 Dec 2025 Pengumuman Bausch + Lomb Announces Two Board of Directors Appointments
12 Dec 2025 Pengumuman Bausch + Lomb Announces Refinancing of Outstanding Term B Loans
08 Dec 2025 Pengumuman Bausch Health Announces Early Exchange Offer Results for Exchange Offers
01 Dec 2025 Pengumuman Bausch Health's Aesthetics Business, Solta Medical, Acquires Longtime Distribution Partner, the Shibo Group, to Strengthen Presence in China
24 Nov 2025 Pengumuman Bausch Health Announces Launch of Offers to Exchange Certain Existing Senior Secured Notes
18 Nov 2025 Pengumuman Bausch + Lomb to Participate in Citi Global Healthcare Conference
18 Nov 2025 Pengumuman Bausch Health to Participate in the 8th Annual Evercore Healthcare Conference
13 Nov 2025 Pengumuman Bausch + Lomb to Highlight Company Transformation and Growth Strategy at Investor Day
10 Nov 2025 Pengumuman Bausch + Lomb Reports More Than 690,000 Pounds of Contacts Lens, Lens Care and Eye Care Materials Collected Through ONE By ONE Recycling Program
05 Nov 2025 Pengumuman Bausch Health's OraPharma Expands into Canada and Puerto Rico, Helping to Address Unmet Needs in Periodontal Disease
03 Nov 2025 Pengumuman Bausch + Lomb to Hold Investor Day on Nov. 13
29 Oct 2025 Pengumuman Bausch Health Announces Third Quarter 2025 Results
29 Oct 2025 Pengumuman Bausch + Lomb Announces Third-Quarter 2025 Results
Papar semua

Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.

Portfolio

AI Templat

Peringatan harga anda

Profil Risiko

| | | | |
Konservatif
Sederhana Konservatif
Sederhana
Sederhana Agresif
Agresif
Margin Keselamatan (EP)
Keuntungan Separa (TP1)
Keuntungan Sasaran (TP2)
Kerugian Maksimum (SL)

Penafian: Perkara di atas adalah untuk tujuan ilustrasi sahaja dan BUKAN nasihat pelaburan. Dapatkan nasihat daripada penasihat kewangan yang berkelayakan.

Harga Masuk (EP)

Ambil Untung 1 (TP1)

Ambil Untung 2 (TP2)

Henti Rugi (SL)

Julat 52 Minggu
 
52WL
 
52WH
SL
EP
TP1
TP2

Semua harga peringatan berada dalam julat harga 52 minggu

Keuntungan Nyata -
Keuntungan Tidak Nyata -
Dividen Diterima 2026 -
Jumlah Untung -
Pulangan Purata -
Kuantiti (Beli) -
Purata Harga (Beli) -
Kuantiti (Jual) -
Purata Harga (Jual) -
Tiada saham yang memenuhi kriteria anda